Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway

• 主要な著者: Jiali Wang (著者), Xianhai He (著者), Zhirong Jia (著者), Aiwen Yan (著者), Kang Xiao (著者), Shuo Liu (著者), Mengjun Hou (著者), Yaling Long (著者), Xuansheng Ding (著者)
• フォーマット: 図書
• 出版事項: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

AbstractContext Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Gefitinib is a first-line treatment for NSCLC. However, its effectiveness is hindered by the development of drug resistance. At present, Shenqi Fuzheng injection (SFI) is widely accepted as an adjuvant therapy...